Morepen Laboratories Reports Strong Q3 FY26 Performance Driven by Medical Devices

Morepen Laboratories Limited reported a consolidated gross revenue of 488 crore for Q3 FY26, marking a 17% increase from Q2 FY26.

The Pharma Business contributed 285 crore to the standalone gross revenue in Q3 FY26, representing 62% of the total business segments.

The Medical Devices segment generated a total revenue of 177 crore in Q3 FY26, showing a significant 44% growth compared to Q3 FY25. This segment accounted for 38% of the total business segments.

Top-selling products in the Medical Devices segment include Blood Glucose meters, BP Monitors, Nebulisers, Thermometers, Ortho Supports, and Pregnancy Kits.

For Q3 FY26, the consolidated EBITDA was 50 crore, a 42% increase from Q2 FY26. The consolidated PAT stood at 28 crore, an 83% increase from Q2 FY26.

In Q3 FY26, India contributed 64.1% of the gross revenue, followed by Europe at 17.1%, Asia at 13.2%, S. America at 2.7%, and USA at 3%.

Cumulatively year-to-date, Morepen has sold 16.85 million Gluco Meters and 2.33 billion Gluco Strips, indicating a strong customer base in this category.